Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

FONAR Announces Fiscal 2015 3rd Quarter Earnings

FONR

MELVILLE, NY--(Marketwired - May 11, 2015) - FONAR Corporation (NASDAQ: FONR)

  • Third Quarter Fiscal 2015 Diluted Net Income Per Common Share Available to Common Shareholders increased 19% to $0.31, versus Third Quarter Fiscal 2014
  • Third Quarter Fiscal 2015 Net Income increased 17% to $2.5 million verses Third Quarter Fiscal 2014
  • Third Quarter Fiscal 2015 Net Revenues increased 0.3% to $17.1 million versus Third Quarter Fiscal 2014

FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™, reported its financial results for the period ended March 31, 2015. The Company's two industry segments are: development, manufacturing and servicing of the UPRIGHT® Multi-Position™ MRI and management of Stand-Up® MRI (UPRIGHT® MRI) centers. The Company is known as the first Company to invent and manufacture an MRI (Magnetic Resonance) scanner. Leading the list of FONAR's most recent patented inventions is its technology enabling UPRIGHT® full weight-bearing MRI imaging, in contrast to the conventional weightless recumbent MRI imaging. This enables, for the first time, full weight-bearing imaging of all the gravity sensitive regions of the human anatomy, e.g. the spine, brain, hip, knee, ankle, foot, shoulder and pelvis. The FONAR UPRIGHT® Multi-Position™ MRI scanner is the world's only MRI scanner licensed under FONAR's multiple UPRIGHT® MRI patents to scan all the patient's body parts in their normal full weight-bearing UPRIGHT® position.

Statement of Operations Items

Revenues for the third fiscal quarter ended March 31, 2015 were $17.1 million as compared to $17.0 million for the corresponding quarter one year earlier. Revenues increased to $52.2 million for the nine month period ended March 31, 2015 from $51.5 million for the corresponding period one year earlier.

Net Income for the third fiscal quarter ended March 31, 2015 was $2.5 million as compared to $2.1 million for the corresponding quarter one year earlier, an increase of 17%. Net Income increased 5% to $9.2 million for the nine month period ended March 31, 2015 from $8.8 million for the corresponding period one year earlier.

Income from Operations increased 15% to $2.7 million for the third fiscal quarter ended March 31, 2015 as compared to $2.3 million for the corresponding quarter one year earlier. Income from Operations was $9.7 million for the nine month periods ended March 31, 2015 and March 31, 2014.

Diluted Net Income Per Common Share Available to Common Shareholders for the third fiscal quarter ended March 31, 2015 increased 19% to $0.31 as compared to $0.26 for the corresponding quarter one year earlier. Diluted Net Income Per Common Share Available to Common Shareholders for the nine month periods ended March 31, 2015 increased 14% to $1.09 from $0.96 for the corresponding period one year earlier.

Balance Sheet Items

Total Assets at the quarter ended March 31, 2015 were $74.5 million, as compared to $76.8 million at June 30, 2014.

Total Current Assets at the quarter ended March 31, 2015 were $43.1 million, as compared to $42.8 million at June 30, 2014.

Total Cash and Cash Equivalents March 31, 2015, were $7.8 million, as compared to $10.0 million at June 30, 2014. Five million cash was used by the Company to purchase 20% of the Class A Members ownership interest in Health Diagnostic Management on January 8, 2015.

Total Liabilities at the quarter ended March 31, 2015 were $27.5 million, as compared to $30.9 million at June 30, 2014.

Total Current Liabilities at the quarter ended March 31, 2015 were $20.3 million, as compared to $21.2 million at June 30, 2014.

Management Discussion

Raymond V. Damadian, president and chairman of Fonar Corporation, said, "The periodic cuts in MRI reimbursements brought about by the Affordable Care Act have subsided, at least for now. Because the Company has a winning strategy and strong management team we continue to make more and more profit and I am happy to report that our diluted net income per common share available to common stockholders has increased by 19% last quarter over the quarter that ended one year earlier (March 31, 2015 vs 2014). In addition, much of our success is due to the medical need met by our cutting edge UPRIGHT® full weight-loaded MRI scanner."

By continuing to educate the medical community about the unique diagnostic advantages of UPRIGHT® Multi-Position™ full weight-loaded MRI, we expect increase scan volume at our existing imaging centers. We also expect growth to come through adding UPRIGHT® imaging centers that we manage," said Dr. Damadian.

Dr. Damadian continued, "On January 8, 2015, the Company acquired 20% of the Class A members ownership interest in Health Diagnostic Management LLC for a cost of approximately $5.0 million, bringing its ownership interest in Health Diagnostic Management LLC to 60.4% from 50.5%. The corresponding impact for FONAR and thus to our shareholders is that this transaction adds to net income and to diluted net income per common share available to common stockholders.

Significant Events

The Company will hold its annual meeting on June 15, 2015. Dr. Damadian has issued his annual shareholder letter which can be seen on the Company's Web site at www.fonar.com/shareholder_letter.htm.

Recently a medical monograph was published by S. Karger, AG based in Basel, Switzerland (see www.karger.com/Book/Home/261956). It is titled "The Craniocervical Syndrome and MRI," and highlights the FONAR UPRIGHT® Multi-Position MRI. It also highlights the recently discovered syndrome that shows how neck injury can interfere with cerebrospinal fluid (CSF) flow in the brain, causing a variety of brain diseases. For more details and a press release visit www.fonar.com

About FONAR

FONAR (NASDAQ: FONR), Melville, NY, The Inventor of MR Scanning™, was incorporated in 1978, and is the first, oldest and most experienced MRI company in the industry. FONAR introduced the world's first commercial MRI in 1980, and went public in 1981. FONAR's stellar product is the UPRIGHT® MRI (also known as the Stand-Up® MRI), the only whole-body MRI that performs Position™ imaging (pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position. The FONAR UPRIGHT® MRI often sees the patient's problem that other scanners cannot because they are lie-down and "weightless" only scanners. The patient-friendly UPRIGHT® MRI has a near-zero claustrophobic rejection rate by patients. As a FONAR customer states, "If the patient is claustrophobic in this scanner, they'll be claustrophobic in my parking lot." Approximately 85% of patients are scanned sitting while they watch a 42" flat screen TV. FONAR is headquartered on Long Island, New York.

UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR Scanning™, Full Range of Motion™, Multi-Position™, Upright Radiology™, The Proof is in the Picture™, True Flow™, pMRI™, Spondylography™, Dynamic™, Spondylometry™, CSP™, and Landscape™, are trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission.

 
 
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
ASSETS
         
    March 31,
2015
  June 30,
2014 *
Cash and cash equivalents   $ 7,828   $ 9,952
Accounts receivable - net     4,071     4,450
Accounts receivable - related party     30     -
Medical receivable - net     9,037     8,808
Management and other fees receivable - net     14,618     11,970
Management and other fees receivable - related medical practices - net     3,669     3,427
Costs and estimated earnings in excess of billing on uncompleted contracts     681     760
Inventories     2,286     2,444
Prepaid expenses and other current assets     855     1,011
Total Current Assets     43,075     42,822
Deferred income tax asset     5,740     5,740
Property and equipment - net     13,454     15,030
Goodwill     1,767     1,767
Other intangible assets - net     9,653     10,509
Other assets     853     922
Total Assets   $ 74,542   $ 76,790
             
             
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
LIABILITIES AND STOCKHOLDERS' EQUITY
         
    March 31,
2015
  June 30,
2014 *
Current Liabilities:            
  Current portion of long-term debt and capital leases   $ 2,896   $ 2,891
  Accounts payable     2,304     2,482
  Other current liabilities     8,994     9,024
  Unearned revenue on service contracts     4,232     4,731
  Unearned revenue on service contracts - related party     28     -
  Customer advances     1,668     1,927
  Billings in excess of costs and estimated earnings on uncompleted contracts     142     142
    Total Current Liabilities     20,264     21,197
Long-Term Liabilities:            
  Deferred income tax liability     584     584
  Due to related medical practices     232     234
  Long-term debt and capital leases, less current portion      6,311     8,482
  Other liabilities     156     386
    Total Long-Term Liabilities     7,283     9,686
    Total Liabilities     27,547     30,883
                 
                 
STOCKHOLDERS' EQUITY:                
Class A non-voting preferred stock $.0001 par value; 453 shares authorized at March 31, 2015 and June 30, 2014, 313 issued and outstanding at March 31, 2015 and June 30, 2014     -       -  
Preferred stock $.001 par value; 567 shares authorized at March 31, 2015 and June 30, 2014, issued and outstanding - none     -       -  
Common Stock $.0001 par value; 8,500 shares authorized at March 31, 2015 and June 30, 2014, 6,062 and 6,057 issued at March 31, 2015 and June 30, 2014, respectively; 6,051 and 6,046 outstanding at March 31, 2015 and June 30, 2014, respectively     1       1  
Class B Common Stock (10 votes per share) $ .0001 par value; 227 shares authorized at March 31, 2015 and June 30, 2014, .146 issued and outstanding at March 31, 2015 and June 30, 2014     -       -  
Class C Common Stock (25 votes per share) $.0001 par value; 567 shares authorized at March 31, 2015 and June 30, 2014, 383 issued and outstanding at March 31, 2015 and June 30, 2014     -       -  
Paid-in capital in excess of par value     175,413       175,284  
Accumulated deficit     (142,047 )     (149,259 )
Notes receivable from employee stockholders     (33 )     (39 )
Treasury stock, at cost - 12 shares of common stock at March 31, 2015 and June 30, 2014    
 (675
)    
 (675
)
Total Fonar Corporation Stockholder Equity     32,659       25,312  
Noncontrolling interests     14,336       20,595  
Total Stockholders' Equity     46,995       45,907  
Total Liabilities and Stockholders' Equity   $ 74,542     $ 76,790  
 *Condensed from audited financial statements.                
                 
 
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts and shares in thousands, except per share amounts)
 (UNAUDITED)
       
    FOR THE THREE MONTHS ENDED MARCH 31  
REVENUES   2015     2014  
  Product sales - net   $ 160     $ 478  
  Service and repair fees - net     2,299       2,518  
  Service and repair fees - related parties - net     27       27  
  Patient fee revenue, net of contractual allowances and discounts     7,284       6,090  
  Provision for bad debts for patient fee     (3,201 )     (2,868 )
  Management and other fees - net     8,653       8,538  
  Management and other fees - related medical practices - net     1,874       2,257  
    Total Revenues - Net     17,096       17,040  
COSTS AND EXPENSES                
  Costs related to product sales     352       223  
  Costs related to service and repair fees     630       623  
  Costs related to service and repair fees - related parties     7       7  
  Costs related to patient fee revenue     2,044       1,947  
  Costs related to management and other fees     5,285       5,327  
  Costs related to management and other fees - related medical practices     1,284       1,318  
  Research and development     360       360  
  Selling, general and administrative     3,706       3,935  
  Provision for bad debts     762       981  
    Total Costs and Expenses     14,430       14,721  
Income From Operations     2,666       2,319  
Interest Expense     (169 )     (203 )
Investment Income     52       57  
Other Income     -       39  
Income Before Provision for Income Taxes and Noncontrolling Interests     2,549       2,212  
Provision for Income Taxes     30       65  
Net Income     2,519       2,147  
Net Income - Noncontrolling Interests     (500 )     (408 )
Net Income - Controlling Interests   $ 2,019     $ 1,739  
Net Income Available to Common Stockholders   $ 1,888     $ 1,625  
Net Income Available to Class A Non-Voting Preferred Stockholders   $ 98     $ 82  
Net Income Available to Class C Common Stockholders   $ 33     $ 29  
Basic Net Income Per Common Share Available to Common Stockholders   $ 0.31     $ 0.27  
Diluted Net Income Per Common Share Available to Common Stockholders   $ 0.31     $ 0.26  
Basic and Diluted Income Per Share-Class C Common   $ 0.09     $ 0.08  
Weighted Average Basic Shares Outstanding-Common Stockholders     6,050       6,022  
Weighted Average Diluted Shares Outstanding - Common Stockholders     6,178       6,150  
Weighted Average Basic Shares Outstanding - Class C Common     383       383  
Weighted Average Diluted Shares Outstanding - Class C Common     383       383  
                 
                 
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts and shares in thousands, except per share amounts)
 (UNAUDITED)
    FOR THE NINE MONTHS ENDED MARCH 31,  
REVENUES   2015     2014  
  Product sales - net   $ 1,806     $ 1,261  
  Service and repair fees - net     7,288       7,578  
  Service and repair fees - related parties - net     83       83  
  Patient fee revenue, net of contractual allowances and discounts     20,700       17,811  
  Provision for bad debts for patient fee     (9,244 )     (7,130 )
  Management and other fees - net     26,004       24,955  
  Management and other fees - related medical practices - net     5,536       6,923  
    Total Revenues - Net     52,173       51,481  
COSTS AND EXPENSES                
  Costs related to product sales     1,674       902  
  Costs related to service and repair fees     1,611       1,755  
  Costs related to service and repair fees - related parties     18       19  
  Costs related to patient fee revenue     5,845       5,823  
  Costs related to management and other fees     15,665       15,591  
  Costs related to management and other fees - related medical practices     3,893       3,808  
  Research and development     1,116       1,128  
  Selling, general and administrative     11,108       12,024  
  Provision for bad debts     1,540       763  
    Total Costs and Expenses     42,470       41,813  
Income From Operations     9,703       9,668  
Interest Expense     (545 )     (682 )
Investment Income     173       178  
Other Expense     (2 )     (113 )
Income Before Provision for Income Taxes and Noncontrolling Interests     9,329       9,051  
Provision for Income Taxes     99       235  
Net Income     9,230       8,816  
Net Income - Noncontrolling Interests     (2,018 )     (2,497 )
Net Income - Controlling Interests   $ 7,212     $ 6,319  
Net Income Available to Common Stockholders   $ 6,743     $ 5,907  
Net Income Available to Class A Non-voting Preferred Stockholders   $ 350     $ 307  
Net Income Available to Class C Common Stockholders   $ 119     $ 105  
Basic Net Income Per Common Share Available to Common Stockholders   $ 1.11     $ 0.98  
Diluted Net Income Per Common Share Available to Common Stockholders   $ 1.09     $ 0.96  
Basic and Diluted Income Per Share-Class C Common   $ 0.31     $ 0.27  
Weighted Average Basic Shares Outstanding - Common Stockholders     6,050       6,002  
Weighted Average Diluted Shares Outstanding- Common Stockholders     6,178       6,130  
Weighted Average Basic Shares Outstanding - Class C Common     383       383  
Weighted Average Diluted Shares Outstanding - Class C Common     383       383  
                 

Contact:
Daniel Culver
Director of Communications
E-mail: Email Contact
www.fonar.com

The Inventor of MR Scanning™
An ISO 9001 Company
Melville, New York 11747
Phone: (631) 694-2929
Fax: (631) 390-1709



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today